1,036
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Botulinum Toxin Injection for Masseteric Hypertrophy Using 6 Point Injection Technique – A Case Report. Proposal of a Clinical Technique to Quantify Prognosis

ORCID Icon &
Pages 45-49 | Received 05 Dec 2022, Accepted 09 Mar 2023, Published online: 21 Mar 2023

References

  • Cheng J, Hsu SH, McGee JS. Botulinum toxin injections for masseter reduction in East Asians. Dermatol Surg. 2019;45:566–572. doi:10.1097/DSS.0000000000001859
  • Kwon K-H, Shin KS, Yeon SH, et al. Application of botulinum toxin in maxillofacial field: part I. Bruxism and square jaw. Maxillofac Plast Reconstr Surg. 2019;41(1):38. doi:10.1186/s40902-019-0218-0
  • Simpson LL. Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs. Biochimie. 2000;82:943–953. doi:10.1016/S0300-9084(00)01169-X
  • Freund B, Schwartz M, Symington JM. The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral Maxillofac Surg. 1999;57:916–20; discussion 920–1. doi:10.1016/S0278-2391(99)90007-1
  • Yeh Y-T, Peng J-H, Peng H-LP. Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy. J Cosmet Dermatol. 2018;17:675–687. doi:10.1111/jocd.12721
  • Kwon K-H, Shin KS, Yeon SH, et al. Application of botulinum toxin in maxillofacial field: part III. Ancillary treatment for maxillofacial surgery and summary. Maxillofac Plast Reconstr Surg. 2019;41(1):45. doi:10.1186/s40902-019-0226-0
  • Rauso R, Lo Giudice G, Tartaro G, et al. Botulinum toxin type A injections for masticatory muscles hypertrophy: a systematic review. J Craniomaxillofac Surg. 2022;50(1):7–18. doi:10.1016/j.jcms.2021.09.019
  • Kim HJ, Yum K-W, Lee S-S, et al. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003;29:484–489. doi:10.1046/j.1524-4725.2003.29117.x
  • von Lindern JJ, Niederhagen B, Appel T, et al. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg. 2001;107:327–332. doi:10.1097/00006534-200102000-00004
  • Bae J-H, Choi D-Y, Lee J-G, et al. The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy. Dermatol Surg. 2014;40(12):1334–1339. doi:10.1097/DSS.0000000000000223
  • Mandel L, Tharakan M. Treatment of unilateral masseteric hypertrophy with botulinum toxin: case report. J Oral Maxillofac Surg. 1999;57:1017–1019. doi:10.1016/S0278-2391(99)90029-0
  • Quezada-Gaon N, Wortsman X, Peñaloza O, et al. Comparison of clinical marking and ultrasound-guided injection of Botulinum type A toxin into the masseter muscles for treating bruxism and its cosmetic effects. J Cosmet Dermatol. 2016;15(3):238–244. doi:10.1111/jocd.12208
  • To EW, Ahuja AT, Ho WS, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg. 2001;54:197–200. doi:10.1054/bjps.2000.3526
  • Xie Y, Zhou J, Li H, et al. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment. Plast Reconstr Surg. 2014;134(2):209e–218e. doi:10.1097/PRS.0000000000000371
  • Shome D, Vadera S, Shiva Ram M, et al. Efficacy of Incobotulinum toxin-A for the treatment of masseter muscle hypertrophy in Asian Indian patients: a 2-year follow-up study. J Cosmet Dermatol. 2020;19(8):1892–1899. doi:10.1111/jocd.13552